HOME >> BIOLOGY >> NEWS
'Man's best friend' may be even better

ng-Plough Research Institute, Kenilworth, NJ. Their findings appear in the May 2003 edition of the Journal of Applied Physiology.

Methodology

Beagles, sensitized to ragweed allergen at birth, were subjected to inhalation of the ragweed extract into the lower respiratory tract inducing a systemic anaphylactic response that manifested in bronchoconstriction, alteration of a breathing pattern, increase in bronchial mucociliary clearance, and temporary cardiovascular depression. The researchers believed that, in these dogs, exclusive exposure of the upper respiratory tract to the same ragweed allergen would precipitate the development of allergic rhinitis that was responsive to treatment with a-adrenergic agonists.

To test this hypothesis, they evaluated the degree of nasal congestion induced by ragweed and histamine in cohorts of ragweed-sensitized, sham-sensitized, and nonsensitized dogs. Nasal congestion was assessed by the measurement of the resistance to conducting air, i.e., nasal airway resistance (RNA) and the relative cross-sectional areas and the volume of nasal passages.

Three series of experiments were conducted on subgroups selected from 14 adult beagle dogs of both sexes, weighing 9.514.5 kg. Five dogs were neonatally sensitized to ragweed, three were their sham-sensitized littermates, and six dogs were nonsensitized. Newborn dogs were sensitized with intraperitoneal injections containing ragweed extract in a saline mix and aluminum hydroxide within 24 hours of birth. Injections were repeated weekly for six weeks and biweekly until 16 weeks of age. In the sham-sensitized animals, only the aluminum hydroxide in saline was injected. Five-milliliter samples of venous blood were drawn from each dog beginning at four months of age and thereafter four times per year to measure serum ragweed-specific IgE levels.

These sensitization and sham sensitization procedures were conducted in November 1992 (two dogs), J
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
17-Jun-2003


Page: 1 2 3 4

Related biology news :

1. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
2. Microbes eat their way to better concrete
3. Computer database being developed at Temple will allow for better inventory of chemicals
4. New and better drugs for tuberculosis goal of UH professor
5. Ants protect plants better when jacked up on nectar
6. The blind really do hear better
7. Microarrays, key genome expression trackers, work better when probes are sequence-verified
8. Researchers develop better understanding of immune response to viral infection
9. Crack babies do better when placed with non-family caregivers
10. A better way to copy DNA
11. Gene profiles could improve acute leukemia diagnosis and lead to better treatments

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Man best friend may even better

(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: